Encapsulating peritoneal sclerosis - An overview

Nephrologie et Therapeutique

Volumn 7, Issue 3, 2011, Pages 162-171

  Braun, Niko ^a   Alscher, Mark Dominik ^a   Kimmel, Martin ^a   Amann, Kerstin ^b   Büttner, Maike ^b  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Encapsulating peritoneal sclerosis; Peritoneal dialysis

Indexed keywords

ANTIFIBROTIC AGENT; CORTICOSTEROID; PREDNISOLONE;

CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MORPHOLOGY; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PARENTERAL NUTRITION; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; REVIEW; RISK FACTOR; UREMIA;

EID: 79958051525     PISSN: 17697255     EISSN: 18729177     Source Type: Journal    
DOI: 10.1016/j.nephro.2010.12.011     Document Type: Short Survey

References (83)

1. Brown MC, Simpson K, Kerssens JJ, Mactier RA. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009;4:1222-9.
2. Johnson DW, Cho Y, Livingston BE, Hawley CM, McDonald SP, Brown FG, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010;77:904-12.
3. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International society for peritoneal dialysis ad hoc committee on ultrafiltration management in peritoneal dialysis. Perit Dial Int 2000;20(Suppl 4):S43-55.
4. Lo WK, Kawanishi H. Encapsulating peritoneal sclerosis-medical and surgical treatment. Perit Dial Int 2009;29(Suppl 2):S211-4.
5. Brown EA, Van Biesen W, Finkelstein FO, Hurst H, Johnson DW, Kawanishi H, et al. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int 2009;29:595-600.
6. Summers A, Alferso C, Abrahams M, Alscher D, Betjes M, Els W, et al. A collaborative approach to understanding EPS: the European EPS working group. Perit Dial Int 2011; in press.
7. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004;44:729-37. (Pubitemid 39237618)
8. Kawanishi H, Moriishi M. Epidemiology of encapsulating peritoneal sclerosis in Japan. Perit Dial Int 2005;25(Suppl 4):S14-8.
9. Nakamura S, Niwa T. Advanced glycation end-products and peritoneal sclerosis. Semin Nephrol 2004;24:502-5. (Pubitemid 39361063)
10. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006;17:199-207.
11. Alscher DM, Braun N, Biegger D, Fritz P. Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am J Kidney Dis 2007;49:452-61.
12. Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract 2009;111:c149-54 [discussion c154].
13. Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 2005;25(Suppl 4):S19-29.
14. Schmidt DW, Flessner MF. Pathogenesis and treatment of encapsulating peritoneal sclerosis: basic and translational research. Perit Dial Int 2008;28(Suppl 5):S10-5.
15. Bozkurt D, Cetin P, Sipahi S, Hur E, Nar H, Ertilav M, et al. The effects of renin-angiotensin system inhibition on regression of encapsulating peritoneal sclerosis. Perit Dial Int 2008;28(Suppl 5):S38-42.
16. Jing S, Kezhou Y, Hong Z, Qun W, Rong W. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients. Nephrology (Carlton) 2010;15:27-32.
17. Hardie EM, Rottman JB, Levy JK. Sclerosing encapsulating peritonitis in four dogs and a cat. Vet Surg 1994;23:107-14.
18. Duman S, Wieczorowska-Tobis K, Styszynski A, Kwiatkowska B, Breborowicz A, Oreopoulos DG. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. Adv Perit Dial 2004;20:31-6.
19. Garosi G, Gaggiotti E, Monaci G, Brardi S, Di Paolo N. Biocompatibility of a peritoneal dialysis solution with amino acids: histological evaluation in the rabbit. Perit Dial Int 1998;18:610-9. (Pubitemid 29094968)
20. Styszynski A, Kwiatkowska B, Wieczorowska-Tobis K, Breborowicz A, Oreopoulos DG. Glucose and mannitol have different effects on peritoneal morphology in chronically dialyzed rats. Adv Perit Dial 2003;19:15-9.
21. Garosi G, Cappelletti F, Di Paolo N. Fibrosis and sclerosis: different disorders or different stages? Contrib Nephrol 2006;150:62-9.
22. Wieczorowska K, Khanna R, Moore HL, Nolph KD, Twardowski ZJ. Rat model of peritoneal fibrosis: preliminary observations. Adv Perit Dial 1995;11:48-51.
23. Park SH, Kim YL, Lindholm B. Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment. Perit Dial Int 2008;28(Suppl 5):S21-8.
24. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995;47:287-91.
25. Mackow RC, Winchester JF, Argy WP, Andrews PM, Fields PA, Bates S, et al. Sclerosing encapsulating peritonitis in rats: an experimental study with intraperitoneal antiseptics. Contrib Nephrol 1987;57:213-8.
26. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. New animal models for encapsulating peritoneal sclerosis-role of acidic solution. Perit Dial Int 2001;21(Suppl 3):S349-53.
27. Levine S, Saltzman A. Abdominal cocoon: an animal model for a complication of peritoneal dialysis. Perit Dial Int 1996;16:613-6. (Pubitemid 127541302)
28. Hoff CM. Experimental animal models of encapsulating peritoneal sclerosis. Perit Dial Int 2005;25(Suppl 4):S57-66.
29. Mackow RC, Argy WP, Winchester JF, Rakowski TA, Fields PA, Rotellar C, et al. Sclerosing encapsulating peritonitis in rats induced by long-term intraperitoneal administration of antiseptics. J Lab Clin Med 1988;112:363-71.
30. Devuyst O, Margetts PJ, Topley N. The pathophysiology of the peritoneal membrane. J Am Soc Nephrol 2010;21:1077-85.
31. Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM, Teerlink T. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Perit Dial Int 1999;19:325-33.
32. Schwenger V. GDP and age receptors: mechanisms of peritoneal damage. Contrib Nephrol 2006;150:77-83. (Pubitemid 44155335)
33. Nakamoto H. Encapsulating peritoneal sclerosis - a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005;25(Suppl 4):S30-8.
34. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992;12:14-27.
35. Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008;3:720-8.
36. Garosi G, Di Paolo N, Sacchi G, Gaggiotti E. Sclerosing peritonitis: a nosological entity. Perit Dial Int 2005;25(Suppl 3):S110-2.
37. Nakayama M, Maruyama Y, Numata M. Encapsulating peritoneal sclerosis is a separate entity. Con. Perit Dial Int 2005;25(Suppl 3):S107-9.
38. Di Paolo N, Sacchi G, De Mia M, Gaggiotti E, Capotondo L, Rossi P, et al. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron 1986;44:204-11. (Pubitemid 16002544)
39. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif 1989;7:74-85. (Pubitemid 19115540)
40. Honda K, Nitta K, Horita S, Yumura W, Nihei H. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996;72:171-6. (Pubitemid 26035372)
41. Pollock CA, Ibels LS, Eckstein RP, Graham JC, Caterson RJ, Mahony JF, et al. Peritoneal morphology on maintenance dialysis. Am J Nephrol 1989;9:198-204. (Pubitemid 19168642)
42. Verger C, Brunschvicg O, Le Charpentier Y, Lavergne A, Vantelon J. Structural and ultrastructural peritoneal membrane changes and permeability alterations during continuous ambulatory peritoneal dialysis. Proc Eur Dial Transplant Assoc 1981;18:199-205.
43. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-9. (Pubitemid 34106290)
44. Honda K, Nitta K, Horita S, Tsukada M, Itabashi M, Nihei H, et al. Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003;19:169-75.
45. Sherif AM, Yoshida H, Maruyama Y, Yamamoto H, Yokoyama K, Hosoya T, et al. Comparison between the pathology of encapsulating sclerosis and simple sclerosis of the peritoneal membrane in chronic peritoneal dialysis. Ther Apher Dial 2008;12:33-41. (Pubitemid 351197450)
46. Lambie ML, John B, Mushahar L, Huckvale C, Davies SJ. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int 2010;78(6):611-8.
47. Tarzi RM, Lim A, Moser S, Ahmad S, George A, Balasubramaniam G, et al. Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis. Clin J Am Soc Nephrol 2008;3:1702-10.
48. Ti JP, Al-Aradi A, Conlon PJ, Lee MJ, Morrin MM. Imaging features of encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. AJR Am J Roentgenol 2010;195:W50-4.
49. Vlijm A, Stoker J, Bipat S, Spijkerboer AM, Phoa SS, Maes R, et al. Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2009;29:517-22.
50. Brown EA. Computed tomographic scanning and diagnosis of encapsulating peritoneal sclerosis. Perit Dial Int 2009;29:502-4.
51. Braun N, Reimold F, Biegger D, Fritz P, Kimmel M, Ulmer C, et al. Fibrogenic growth factors in encapsulating peritoneal sclerosis. Nephron Clin Pract 2009;113:c88-95.
52. Braun N, Kimmel M, Biegger D, Fritz P, Alscher DM. Angiogenesis and cellularity in encapsulating peritoneal sclerosis. Nephrol Dial Transplant Plus 2010;3:414-5.
53. Braun N, Alscher DM, Fritz P, Edenhofer I, Kimmel M, Gaspert A, et al. Podoplanin-positive cells are a hallmark of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2010;26(3):1033-41.
54. Kawanishi H, Ide K, Yamashita M, Shimomura M, Moriishi M, Tsuchiya S, et al. Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis. Adv Perit Dial 2008;24:51-5.
55. Kawanishi H, Harada Y, Noriyuki T, Kawai T, Takahashi S, Moriishi M, et al. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 2001;17:200-4.
56. Yamamoto H, Nakayama M, Yamamoto R, Otsuka Y, Takahashi H, Kato N, et al. Fifteen cases of encapsulating peritoneal sclerosis related to peritoneal dialysis: a single-center experience in Japan. Adv Perit Dial 2002;18:135-8.
57. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 2005;25:285-7. (Pubitemid 40724209)
58. Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007;27:619-24.
59. Nakamoto H, Imai H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int 2008;28(Suppl 3):S83-7.
60. Li YC. Renoprotective effects of vitamin D analogs. Kidney Int 2010;78:134-9.
61. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006;144:101-6. (Pubitemid 46768228)
62. del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, Costero O, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003;19:32-5.
63. Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006;26:203-6. (Pubitemid 44336172)
64. Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley PE, Augustine T, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005;68:2381-8. (Pubitemid 43117819)
65. Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, Betjes MG. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch multicentre EPS study. Am J Transplant 2011;11(3):599-605.
66. De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by rage and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006;21:2549-55. (Pubitemid 44644530)
67. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West-Mays JA, et al. Transient overexpression of tgf-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005;16:425-36. (Pubitemid 41725138)
68. Kropp J, Sinsakul M, Butsch J, Rodby R. Laparoscopy in the early diagnosis and management of sclerosing encapsulating peritonitis. Semin Dial 2009;22:304-307.
69. Noble TB. Plication of small intestine as prophylaxis against adhesions. Am J Surg 1937;35:41-6.
70. de Freitas D, Jordaan A, Williams R, Alderdice J, Curwell J, Hurst H, et al. Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. Perit Dial Int 2008;28:271-6. (Pubitemid 352003042)
71. Temprano Ferreras JL, Breton Lesmes I, de la Cuerda Compes C, Camblor Alvarez M, Zugasti Murillo A, Garcia Peris P. Refeeding syndrome. A review. Rev Clin Esp 2005;205:79-86.
72. Korte MR, Yo M, Betjes MG, Fieren MW, van Saase JC, Boer WH, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 2007;22:2412-4. (Pubitemid 47244739)
73. Dejagere T, Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. Am J Kidney Dis 2005;45:e33-7.
74. Temple S, Zaltzman J, Perl J. Development of encapsulating peritoneal sclerosis in a renal transplant recipient on sirolimus immunotherapy. Perit Dial Int 2010;30:475-7.
75. Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H, et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005;25(Suppl 4):S83-95.
76. Braun N, Alscher DM, Amann K. Deutsches peritoneal-biopsie register (dpr)-klinische und pathomorphologische aspekte. Der Nephrologe 2010;5:531-3.
77. Jeloka T. No need for an "Expiry date" in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis: comments from around the world. Int Urol Nephrol 2010;42:247.
78. Habib AM, Preston E, Davenport A. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transplant 2010;25:1633-8.
79. Yamamoto R, Otsuka Y, Nakayama M, Maruyama Y, Katoh N, Ikeda M, et al. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol 2005;9:148-52. (Pubitemid 40875105)
80. Wieczorowska-Tobis K, Polubinska A, Breborowicz A, Oreopoulos DG. A comparison of the biocompatibility of phosphate-buffered saline and dianeal 3.86% in the rat model of peritoneal dialysis. Adv Perit Dial 2001;17:42-6.
81. Eleftheriadis T, Antoniadi G, Liakopoulos V, Antoniadis N, Stefanidis I, Galaktidou G. Vitamin D receptor activators and response to injury in kidney diseases. J Nephrol 2010;23:514-24.
82. Kolesnyk I, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT. A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients. Nephrol Dial Transplant 2009;24:272-7.
83. Summers AM. Biomarkers of EPS: can we go "Back to the future"? Perit Dial Int 2010;30:158-60.